ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
September 27 2021 - 7:15AM
Business Wire
ADCT-901 targets KAAG1, a novel tumor target
for ADC development
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs) for patients with hematologic malignancies and solid tumors,
today announced the first patient has been dosed in the Phase 1
clinical trial evaluating ADCT-901, targeting kidney associated
antigen 1 (KAAG1), in patients with selected advanced solid tumors
with high unmet medical needs.
“With the FDA’s clearance of the IND application for ADCT-901,
we are pleased to quickly move this promising new antibody drug
conjugate into clinical development,” said Joseph Camardo, MD,
Chief Medical Officer of ADC Therapeutics. “There is high
expression of KAAG1 in tumors that have few new medicines, such as
ovarian and triple negative breast cancer. We look forward to
further evaluating the safety, antitumor activity and optimal
dosing for ADCT-901 in this Phase 1 trial.”
ADCT-901 is composed of a humanized monoclonal antibody (3A4)
directed against human KAAG1 conjugated through a
cathepsin-cleavable linker to the PBD dimer SG3199, the same
cytotoxin used in ADC Therapeutics’ lead product, ZYNLONTA®. KAAG1
is an attractive, novel tumor target for ADCs expressed on the
membrane of tumor cells, while its expression on healthy tissue is
very limited.
The open-label, dose-escalation and dose-expansion clinical
trial will evaluate the safety, tolerability, pharmacokinetics, and
antitumor activity of ADCT-901 as monotherapy in patients with
selected advanced solid tumors. For more information about the
Phase 1 trial, please visit www.clinicaltrials.gov (identifier
NCT04972981).
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210927005086/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Hamilton ADC Therapeutics
amanda.hamilton@adctherapeutics.com +1 917-288-7023
EU Media Alexandre Müller Dynamics Group amu@dynamicsgroup.ch
+41 (0) 43 268 3231
USA Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com Tel.: +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2023 to Apr 2024